Alembic Pharmaceuticals gets USFDA final approval for Dabigatran Etexilate capsules
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
Cipla had earlier invested € 15 million in Ethris in 2022
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
HaystackAnalytics is engaged in the business of developing genomic analysis software
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Greg was also central to the planning, design, and construction of this facility
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Theophylline is used to treat asthma and chronic obstructive pulmonary disease
Subscribe To Our Newsletter & Stay Updated